Cullinan Therapeutics, Inc. (NASDAQ: CGEM) Investment Analysis

The consensus price target for Cullinan Therapeutics, Inc. (NASDAQ: CGEM) has slightly decreased over the past year but remains stable in recent months.Morgan Stanley analysts have set a price target of $19 for CGEM, indicating a positive outlook for the stock.Cullinan's focus on developing therapies for cancer and immune-related diseases positions it well in the competitive biopharmaceutical industry.Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company that focuses on de ...